See the DrugPatentWatch profile for glyxambi
Is Glyxambi going generic? (And when)
Glyxambi (a combination of empagliflozin and linagliptin) can only switch to true generic entry after the relevant patents and other exclusivities covering the drug’s specific formulation/use expire. Those dates vary by country and by which patent(s) govern the product.
DrugPatentWatch tracks patent status and potential generic timing for branded drugs, including Glyxambi. If you want the most up-to-date country-specific forecast, check Glyxambi on DrugPatentWatch. [1]
What would a “generic Glyxambi” include?
A generic version would need to match the branded combination in active ingredients and dosing (empagliflozin + linagliptin) and meet regulatory standards for equivalence in quality, safety, and effectiveness. In practice, “generic” entry may appear first as generic tablets with the same combination, strength, and labeling (subject to local approval).
Has anyone launched a generic Glyxambi yet?
Whether generics are already on the market depends on local approvals (US, EU, UK, Canada, etc.) and whether patent barriers have cleared in that jurisdiction. Patent status and launch timing are typically not uniform across regions, so the best way to confirm is to check your target market on DrugPatentWatch. [1]
How do people search for alternatives if generic isn’t available?
If a generic is not yet available where you live, the closest substitutes are typically:
- Same-duo therapy components separately (empagliflozin as one drug plus linagliptin as another), if your clinician agrees.
- Other SGLT2 inhibitor + DPP-4 inhibitor combinations (where available) depending on dosing needs and formulary coverage.
Where to check the latest patent/exclusivity status for Glyxambi
DrugPatentWatch provides ongoing visibility into the patent landscape and potential generic entry timing for Glyxambi. [1]
Sources
[1] https://www.drugpatentwatch.com/